G astric and esophageal cancer are major health problems being, respectively, the fourth and eighth most common cancers in the world. 1 Both cancers carry a poor prognosis with a mortality, respectively, of 647,000 and 338,000 cases annually. 1 Cancer of the gastric cardia has an even worse prognosis because of the advanced stage of disease at the time of presentation and the higher incidence of regional lymph node and hepatic metastases. 2, 3 Recent studies have shown that adjuvant therapy and multimodal treatment may improve the prognosis. 4 -6 Curative surgery combined with an adjuvant treatment with mitomycin or metronidazole, both hypoxic cell sensitizers, improves significantly the 5-year survival in gastric cancer. 7, 8 An approach that targets hypoxic cells may indeed be important. Studies performed on cancer of the prostate, head, and neck have shown that tumor hypoxia is an independent predictor of a poor prognosis. 9 Data concerning esophageal and gastric cancer are extremely limited. The growth of a solid tumor depends partially on the development of its own blood supply. This process, called angiogenesis, results in an irregular and chaotic vascular network. Hence, the supply of nutrients and oxygen may still be insufficient resulting in areas of necrosis in the tumor. Tumor hypoxia limits the success of nonsurgical treatment as hypoxic tumor cells are resistant to chemotherapy as well as radiation therapy. 9 The poor outcome is, however, not only due to the resistance to treatment but also to the more aggressive behavior of these cells. Hypoxia selects tumor cells with a reduced apoptotic potential and angiogenic phenotype, which invade the surrounding tissue and easily metastasize due to the activation of matrix metalloproteinases. 10, 11 Hypoxia causes up-regulation of different genes by activation of the hypoxia-inducible transcription factor 1 (HIF-1), which is a heterodimer composed of HIF-1␣ and HIF-1␤. Whereas HIF-1␤ is constitutively expressed, the level of HIF-1␣ is low under normoxic conditions. Intratumoral hypoxia as well as genetic abnormalities stabilize HIF-1␣. 12 This stabilized HIF-1␣ binds to the hypoxia responsive element, present in the promoter regions of several hypoxia-responsible genes, including carbonic anhydrase IX (CA IX) and vascular-endothelial growth factor (VEGF). 13, 14 These genes are involved in tumorigenesis and progression of cancer at different levels such as angiogenesis, cell proliferation, apoptosis, invasion, and dissemination to other organs. VEGF, which is originally known because of its vascular-enhancing permeability function, is a potent angiogenic and mitogenic factor. 15, 16 CA IX (originally named MN) is a member of the ␣-family of carbonic anhydrases of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide to carbonic acid. 17 Carbonic anhydrases are involved in several physiologic and biologic processes in humans. 18 CA IX is not only a highly active enzyme but is also involved in cell-cell adhesion and cell proliferation. 19, 20 Its expression is mostly restricted to the premalignant and malignant cells and rarely found in normal tissue or benign lesions. [21] [22] [23] [24] [25] [26] The purpose of our study was to analyze the expression of CA IX in a series of adenocarcinomas situated at the gastroesophageal junction and in the stomach. As HIF-1␣ is not only a major regulator of the expression of this carbonic anhydrase, but also of VEGF, we evaluated the coexpression of both hypoxia-related proteins. We correlated their expres-sion with the microvessel density (MVD). Finally, these data were correlated to clinicopathologic features, including histologic type of tumor, stage, and prognosis.
MATERIALS AND METHODS

Materials
Our study material consisted of 154 adenocarcinomas of the esophagus, the cardia, and the distal stomach (Table 1) . These adenocarcinomas were collected from the archives of the department of Pathology during the period, end of 1995 to beginning of 2000. Only patients who were treated with a curative intent and underwent a complete resection of the tumor (R0) were included in this study. Other exclusion criteria of this study were preoperative neoadjuvant therapy and a small size of the tumor; thus, patients with a stage I or stage IA were excluded from the study. 27 Patients with postoperative mortality (4 cases) or who died due to reasons not related to tumoral pathology (5 cases) were also excluded from analysis. The lesions were classified according to the International Union Against Cancer (UICC) guidelines. 28 Routine histology was performed on samples of the resection specimen, fixed in formalin, and embedded in paraffin. According to the Lauren classification, the tumors were classified on hematoxylin and eosin-stained sections into the diffuse-or intestinal-type of adenocarcinomas, based on their histopathologic features. Tumors demonstrating mixed histologic features were classified according to their predominant features. 29
Immunohistochemical Analysis
Immunohistochemistry was performed on a tissue block, selected on a hematoxylin and eosin-stained section to be representative for the tumor mass in the resection specimen. For immunohistochemical analysis, we used a CA IX 17, 30 An avidin-biotin method with antigen retrieval was used. The staining was performed on an automated Ventana IHC instrument, using the Ventana basic DAB detection kit. Our immunohistochemical analysis was validated through positive and negative controls (by omitting the primary antibody).
In accordance with the criteria used in literature, the positivity of a tumor for CA IX was evaluated in function of the number of cells showing a membranous positivity (0%-100%) and the intensity of staining (absent ϭ 0, mild ϭ 1, moderate ϭ 2, strong ϭ 3), resulting in a score between 0 and 300. The tumor was considered as being positive for CA IX expression if the score was higher than the median score. 31 Occasionally, some cytoplasmic positivity in the tumor cells was seen, but only membranous staining was considered as positive.
To evaluate the quality of our CA IX immunohistochemical staining, the gastric mucosa was used as a positive internal control. A distinctive pattern of membranous staining of CA IX was observed at the level of the gastric epithelium and the glands, composed of parietal cells and zymogenic cells.
The cytoplasmic VEGF expression was analyzed in function of the number of positively stained tumor cells (0%-100%) and the intensity of the staining (0 -3) in which the final score was the product of both parameters. If this score was higher than the median score, a tumor was regarded as expressing VEGF. 32 The blood vessels and the ganglion cells of the plexus myentericus served as an internal positive control.
To determine the MVD, the blood vessels were stained with a CD31 antibody, which is the most sensitive endothelial marker to date. 33 To evaluate the vascularization of the tumor, areas with the most extensive vascularization, socalled "hot spots," were determined by screening the slide at low power (100ϫ). The MVD, defined as the number of CD31-positive vessels per square millimeter, was determined according to the method of Gundersen et al. 34 For each case, the microvessels were counted in 5 different fields of high vascularity at a magnification of 250ϫ. A CD31-positive single vessel corresponded to a positive endothelial cell or cluster of cells, either with or without a lumen, not necessarily containing erythrocytes. The expression of VEGF and CA IX was evaluated in function of the MVD. Coexpression of VEGF and CA IX was analyzed on serial sections.
Evaluation of the immunohistochemical stains was performed by an investigator unaware of the clinical outcome of disease.
Statistical Analysis
For statistical analysis, we used the 2 -test and the t test, in which P Յ 0.05 was considered statistically significant. The Spearman's rank sum test was used to evaluate the correlation between different examined factors. Survival analysis was performed applying the Kaplan-Meier method and analyzed by the log-rank test. In this analysis, we evaluated the overall survival and the metastasis-free survival, in which the latter was defined as hematogenous spread of the tumor only. Multivariate analysis, using the Cox proportional hazards model, has been performed. In this analysis, we included, besides the more classic clinical parameters (TNM) the lymph node ratio, which was defined as the ratio of the number of involved lymph nodes compared with the total number of lymph nodes, multiplied by 100. 35 The median follow-up of the whole study-population was 21.5 months (range, 2-88 months) with 41 months (range, 6.2-88 months) in the group of surviving patients. The median survival of our study population was 29.7 months (range, 17.4 -42 months).
Results of our study have been presented in part at congresses and been published as abstracts. 36, 37 
RESULTS
The clinical data of our study population are presented in Tables 1 and 2 .
CA IX Expression
The majority of tumors exhibited a moderate to strong membranous staining for CA IX. The overall prevalence of CA IX positivity was 50% (n ϭ 77 of 154). The tumors showed mainly a focal CA IX expression (60%, n ϭ 46 of 77).
The data relating to the immunohistochemical analysis of the CA IX expression in function of the localization and the subtype of the adenocarcinomas are shown in Figure 1 . The overall prevalence of CA IX expression was 50% (n ϭ 77 of 154). CA IX positivity showed no significant difference in prevalence with respect to the localization of the tumor (esophageal adenocarcinomas: n ϭ 19 of 39; 49%; cardiac adenocarcinomas: n ϭ 38 of 73; 52%; and distal gastric adenocarcinomas: n ϭ 20 of 42; 48%). But the prevalence of CA IX expression was significantly higher in intestinal-type 57% (n ϭ 60 of 105) than in diffuse-type adenocarcinomas (35%, n ϭ 17 of 49) (P ϭ 0.015). Although this variation in CA IX positivity in relation to the histologic type was observed for each localization, only in the case of the cardiac adenocarcinomas a statistically significant difference was found between the intestinal-type (60%, n ϭ 32 of 53) and the diffuse-type adenocarcinomas (30%, n ϭ 6 of 20) (P ϭ 0.03) The absolute numbers of patients are given between brackets. ( Figure 1 ). The CA IX expression was not associated with a significant difference in MVD as CA IX-positive tumors (13.74 Ϯ 4.61) had no significant higher MVD than CA IX-negative tumors (12.58 Ϯ 5.11) (P ϭ not significant). The higher prevalence of CA IX positivity in the intestinal-type adenocarcinomas was not related to a higher MVD (P ϭ not significantly). Survival analysis revealed that patients with a CA IX positive tumor have a significantly worse prognosis than those with a CA IX negative tumor, resulting in a significant difference in 5-year survival (27% versus 47%) (P ϭ 0.008) ( Figure 2) . Similarly, intestinal-(median survival 22.7 months versus 38.8 months) as well as diffuse-type adenocarcinomas (median survival 12.5 months versus 29.7 months) were found to have a worse prognosis, if they express CA IX. Al-though not significant, this relationship between prognosis and expression was observed in each localization. Comparison of the CA IX expression with clinicopathologic characteristics of the study population revealed no relationship with the nodal status. However, the expression increased with the depth of invasion as deeply infiltrating tumors, situated in the adventitia or tunica serosa had a significantly higher expression of CA IX (54%, n ϭ 72 of 133), than those situated in the more superficial layers of the wall (24%, n ϭ 5 of 21) (P ϭ 0.02). It was also associated with a higher prevalence of metastases during follow-up: CA IX-positive tumors (56%, n ϭ 43 of 77) versus CA IX-negative tumors (39%, n ϭ 30 of 77) (P ϭ 0.05). Patients with a CA IX-positive tumor had a significant lower metastasis-free survival (18 months versus 54.87 months) with a poorer 5-year survival (28% versus 47%) (P ϭ 0.01).
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Multivariate analysis, using the Cox proportional hazard analysis, was performed in which the clinical parameters were used, which were significant by univariate analysis: depth of invasion (P Ͻ 0.0001), pNϩ (P ϭ 0.0004), and lymph node ratio (P Ͻ 0.0001). This analysis showed that the lymph node ratio (HR ϭ 1.013, 95% CI 1.004 -1.022, P ϭ 0.003) and the CA IX expression (HR ϭ 1.707, 95% CI 1.10 -2.650, P ϭ 0.017) are both independent prognostic factors for overall survival. In case of metastasis-free survival, a similar observation was found for the lymph node ratio (HR ϭ 1.015, 95% CI 1.005-1.026, P ϭ 0.005) as well as the CA IX expression (HR ϭ 1.606, 95% CI 1.020 -2.529, P ϭ 0.041).
VEGF Expression
In 64% of the adenocarcinomas, a cytoplasmic staining for VEGF was detectable (n ϭ 99 of 154) with the following distribution: esophageal adenocarcinomas 69% (n ϭ 27 of 39), cardiac adenocarcinomas 73% (n ϭ 53 of 73), and distal gastric adenocarcinomas 45% (n ϭ 19 of 42) ( Figure 3) . In contrast to the more restricted CA IX expression the majority of tumors showed a diffuse cytoplasmic staining. The expression of VEGF was significantly associated with a high MVD (P Ͻ 0.0001). The VEGF expression did vary with respect to the subtype of the tumor: intestinal-type tumors (86%, n ϭ 90 of 105) expressed more frequently this marker than diffuse-type of adenocarcinomas (18%, n ϭ 9 of 49) (P ϭ 10 Ϫ6 ) (Figure 3) . This difference associated with the histologic subtype of the adenocarcinoma was found at the level of esophagus (P ϭ 0.007), the cardia (P Ͻ 0.0001), as well as the distal stomach (P ϭ 10 Ϫ6 ) (Figure 3 ). In intestinal-as well as diffuse-type adenocarcinomas, there was a strong correlation between VEGF expression and microvessel density (r ϭ 0.465, P Ͻ 0.0001).
Using the Kaplan-Meier method, no relationship was found between VEGF expression and prognosis. The prevalence of VEGF positivity increased significantly in function of the depth of invasion as tumors infiltrating the tunica adventitia or tunica serosa (78%, n ϭ 77 of 99) expressed more frequently this marker than those situated in the more superficial layers (53%, n ϭ 29 of 55) (P ϭ 0.002). During follow-up, VEGF-positive tumors were significantly associated with a hematogenous dissemination pattern (liver and lungs) (78%, n ϭ 38 of 49) than VEGF-negative tumors (34%, n ϭ 10 of 29) (P Ͻ 0.0001). The prevalence of VEGF positivity was not related to the depth of invasion or the presence of pNϩ.
Coexpression of CA IX and VEGF
We assessed the simultaneous expression of CA IX and VEGF on serial sections. Independent of their localization, some tumors showed a coexpression (36%, n ϭ 56 of 154) (Figure 4 ). Using the Spearman's rank sum test, there was a weak, but significant, correlation between CA IX and VEGF expression (r ϭ 0.176, P ϭ 0.03). Coexpression was significantly more frequent in intestinal-type (50%, n ϭ 53 of 105) than in diffusetype adenocarcinomas (6%, n ϭ 3 of 49) (P Ͻ 0.0001).
Coexpression was associated with a deeply infiltrating tumor (86%, n ϭ 48 of 56) compared with the rest of the study-population (59%, n ϭ 58 of 98) (P ϭ 0.001). The prevalence of metastasis showed the following distribution in function of the immunophenotype of the tumor: ͓CA IXϩ, VEGFϩ͔ 52% (n ϭ 29 of 56), ͓CA IXϩ, VEGFϪ͔ 48% (n ϭ 10 of 21), ͓CA IXϪ, VEGFϩ͔ 38% (n ϭ 16 of 43) and ͓CA IXϪ, VEGFϪ͔ 38% (n ϭ 13 of 34). Survival analysis reveals that coexpression was associated with a poor prognosis (P ϭ 0.008). The higher prevalence of metastatic behavior in tumors, coexpressing CA IX and VEGF, also resulted in a significant poorer metastasis free-survival compared with VEGF-positive tumors, (P ϭ 0.05) and those expressing only CA IX (P ϭ 0.03). Multivariate analysis showed however that coexpression is not an independent prognostic indicator of overall survival or metastasis free survival.
DISCUSSION
The development of tumors is associated with 2 paradoxical processes, namely, angiogenesis and chronic hypoxia. This paradox results from the development of a chaotic and immature vascular network, which leads to a heterogeneous inadequate oxygen supply in the tumor. In our study, performed on a series of adenocarcinomas situated in the esophagus and stomach, we investigated this paradox in a defined tumor population by analyzing the expression of CA IX, a marker of hypoxia, and correlating its expression with VEGF, a pro-angiogenic factor. Moreover, we evaluated its clinical significance by performing survival analysis.
CA IX, a highly active carbonic anhydrase, is a novel tumor-associated protein. 38 This tumor marker has been evaluated in several types of solid tumors. In contrast to other organs, the gastrointestinal tract is, however, an exception since different parts of the normal mucosa express this antigen. 39 This protein is expressed in epithelial cells with the highest proliferative capacity, supporting its role in cell proliferation. 40 NIH3T3 fibroblasts, transfected with a plasmid containing the CA IX cDNA, change their phenotype and become an uncontrolled proliferating cell population. 17 Finally, CA IX is not only involved in cell proliferation and cell differentiation, but as a cell surface molecule, it may act in cell-cell communication and cell adhesion. 19 This carbonic anhydrase has been implicated in the regulation of the microenvironmental pH by conversion of carbon dioxide into bicarbonate and hydrogen. Carbon dioxide as well as lactate, produced during the anaerobic glycolysis in tumors, are important sources of acidity in tumors, which promotes tumor 
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Annals of Surgery • Volume 243, Number 3, March 2006 growth and metastasis. 40 -43 Based on these features, CA IX is not only a tumor marker but appears directly involved in the oncogenesis of different types of tumors. In the gastrointestinal tract, its expression has been demonstrated in esophageal, gastric, colorectal, biliary, and pancreatic adenocarcinomas (range, 34%-80%). 26,44 -46 In our study, performed on a large series of esophageal, cardiac, and distal gastric cancer, the overall prevalence of CA IX positivity is 50%. The prevalence of CA IX expression is independent of the localization of the tumor. The percentage of CA IX-positive esophageal adenocarcinomas (49%, n ϭ 19 of 39) in the present study is lower than in the study of Turner et al (80%, n ϭ 8 of 10). 26 However, when using the same criteria, based on the intensity of CA IX expression only, there is no significant difference (80% versus 71%). Controversial results have been published concerning the expression of CA IX in gastric tumors ranging from total absence to 100% expression. 38, 47, 48 However, methodologic problems (heterogeneous type of study material and variable grading systems) hamper comparison. CA IX expression is an independent prognostic factor of overall survival (P ϭ 0.017) and metastasis-free survival (P ϭ 0.041), an observation that has also been described in other tumors, such as breast cancer and non small cell lung cancer. 25, 31 Analysis of different clinicopathologic parameters reveals that CA IX expression is associated with the depth of invasion and with a higher prevalence of metastases (P ϭ 0.05). These findings suggest that CA IX-expressing tumors may have a growth advantage as has been proposed in a study on colorectal cancers. 49 HIF-1␣ does not only bind to the promotor region of CA IX, but also to the promoter region of other hypoxiarelated genes, such as VEGF. 12 In contrast to CA IX, the VEGF expression in our study population shows some variation with respect to the localization of the tumor: cardiac adenocarcinomas (73%) are more frequently VEGF-positive than distal gastric adenocarcinomas (45%) (P ϭ 0.007). This may be related to the difference in prognosis between both localizations: according to literature cardiac adenocarcinomas have a worse prognosis than distal gastric adenocarcinomas, which may be explained by the higher prevalence of hepatic metastases. 2, 3 Although not statistically significant in our study population, patients having a cardiac adenocarcinoma (median survival, 24 months) indeed have a poorer prognosis than those having a distal gastric cancer (median survival, 37.2 months). This poor prognosis is related to the advanced stage of disease (P ϭ 0.0001), pNϩ (P ϭ 0.005), and the metastatic behavior in cardiac adenocarcinomas: hepatic metastasis were more frequently found in association with cardiac (53%, n ϭ 21 of 40) than with distal gastric cancer (25%, n ϭ 4 of 16) as could be expected from literature.
Intestinal-type adenocarcinomas express more frequently VEGF than diffuse-type adenocarcinomas (P ϭ 10 Ϫ6 ). Our results are in accordance with the study of Takahashi et al, which demonstrated a variation of VEGF expression in function of the histologic subtype. 49 VEGF expression has been associated with a hematogenous metastatic behavior. 50 In our study, we identified a subpopulation of tumors, characterized by a coexpression of CA IX and VEGF. This population had a poorer overall survival (P ϭ 0.008) and metastasis-free survival (P ϭ 0.05) by univariate analysis. However, in multivariate analysis, it was not an independent prognostic factor.
Intestinal-type adenocarcinomas express more frequently CA IX (P ϭ 0.015) and VEGF (P ϭ 10 Ϫ6 ) than diffuse-type adenocarcinomas. The Lauren classification is not only based on the morphology of tumors but also reflects the difference in histogenesis and metastatic behavior of both tumors. 29 The strong relationship between intestinal-type adenocarcinomas and CA IX and VEGF expression suggests that the aggressive behavior of this tumor is determined by hypoxia-related and angiogenic-related mechanisms. This may explain the difference in metastatic potential in function of the histologic subtype: intestinal-type adenocarcinomas preferentially metastasize hematogenously, whereas diffuse-type adenocarcinomas are mostly associated with peritoneal dissemination. 51, 52 A similar observation was found in our study population as intestinal-type adenocarcinomas (75%, n ϭ 40 of 53) were more frequently associated with hematogenous metastases than diffuse-type adenocarcinomas (28%, n ϭ 7 of 25) (P Ͻ 0.0001).
Finally, our data demonstrate that the prognosis of patients with adenocarcinomas of the esophagus and the stomach varies significantly in function of CA IX and VEGF expression by the tumor. Although other clinical parameters as the lymph node ratio are independent prognostic factors, multivariate analysis reveals that, in particular, CA IX expression is a determinant of overall survival and metastasisfree survival. The application of this marker may identify a patient population with a higher risk of metastatic disease and may select a subpopulation that could possibly benefit from hypoxic targeting therapy. 53 
